Pricing Log in Create free account
Saturday 17 October 2026 Export AEON’s income statement to Excel — free account

AEON Biopharma, Inc.

AEON Healthcare Biotechnology

In the quarter to June 2026, EPS grew 96.7%, free cash flow fell 76.9% and total debt fell 88.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.23 0.01 −4.17%
Market cap
$12.1M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

AEON Biopharma, Inc. (AEON) P/E ratio

Alert me on P/E ratio

AEON Biopharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 76.5× (May 2022) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change

Against its own ten years

Low 0.0× High 76.5×
Ten-year median 0.0×
Current reading's percentile 55

P/E ratio against peers

Company P/E ratio
AEON AEON Biopharma, Inc. n/m
PLUR Pluri Inc. compare n/m
ENSC Ensysce Biosciences, Inc. compare n/m
CASIF CASI Pharmaceuticals Inc. compare n/m
ACTU Actuate Therapeutics, Inc. compare n/m
CTXR Citius Pharmaceuticals, Inc. compare n/m
INAB IN8bio, Inc. compare n/m
PASG Passage Bio, Inc. compare n/m
ASBP Aspire-Lakewood Holdings, Inc. compare 0.2×
Biotechnology industry median 8.5×
Healthcare sector median 23.0×
Market median 18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on AEON